Therapy News and Research

RSS

Patterns of DNA anomalies can predict outcomes in women with ovarian cancer

Nearly anyone touched by ovarian cancer will tell you: it's devastating. It's bad enough that cancer in almost 80 percent of patients reaches advanced stages before diagnosis, and that most patients are expected to die within five years. But just as painfully, roughly one quarter of women diagnosed have no warning that they are resistant to platinum-based chemotherapy, the main line of defense, nor that they will likely have 18 months to live.

16 Apr 2015

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma. The trial, for which Yale is a lead site, will enroll patients lacking a particular genetic mutation for whom immune therapy did not work or was not an option.

16 Apr 2015

UW researchers use Activa PC+S DBS system to treat essential tremor

Essential tremor, a nervous system disorder that causes a rhythmic shaking in the hands, affects an estimated 10 million Americans and millions more worldwide. Deep brain stimulation, essentially a pacemaker for the brain, has been approved to treat essential tremor. But there is not an existing system that automatically provides electrical stimulation only when needed.

16 Apr 2015

Heroin-assisted treatments benefit some drug users

Drug users who do not benefit from conventional treatments for heroin addiction should be able to access the drug through the health system, urges a Canadian expert in The BMJ today.

16 Apr 2015

NIH-supported clinical trial to test statin use in patients with HIV-related cardiovascular disease

Researchers have begun enrolling participants in a multicenter international clinical trial to test whether statin administration can reduce the risk for major adverse cardiovascular events, such as heart attacks, strokes, and heart disease, in people with HIV infection. The trial is supported by the National Institutes of Health's National Heart, Lung, and Blood Institute and National Institute of Allergy and Infectious Diseases.

16 Apr 2015

UH Seidman Cancer Center uses SpaceOAR System to perform first-ever prostate cancer treatment

The radiation oncology team at UH Seidman Cancer Center at UH Geauga Medical Center performed the first-ever prostate cancer treatment on April 3 using a newly approved device. The device, called SpaceOAR System, enhances the efficacy of radiation treatment by protecting organs surrounding the prostate. The device, a temporary injectable gel, received FDA clearance on April 1.

16 Apr 2015

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.

15 Apr 2015

Warfarin and PT-INR testing: an interview with Paul Wright, CEO, Universal Biosensors

There are roughly 10 million people worldwide taking Warfarin, accounting for more than 200 million point of care (POC) PT-INR tests performed globally each year...

15 Apr 2015

Innovative liver cancer treatment gets EU approval

A new treatment for liver cancer developed by the University Medical Center (UMC) Utrecht has received the European CE mark for quality and safety.

15 Apr 2015

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Cardio3 BioSciences (C3BS), a leader in engineered cell-therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced the enrollment of the first patient in a Phase I clinical trial evaluating the Company’s lead CAR T-Cell therapy, NKG2D CAR T-Cell, in blood cancer patients with acute myeloid leukemia (AML) or multiple myeloma (MM).

15 Apr 2015

Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

Small cell lung cancer (SCLC) will be the concentrated focus when 100 global experts in the field meet for a workshop hosted by the International Association for the Study of Lung Cancer on April 22-24, 2015 at Memorial Sloan Kettering Cancer Center in New York City.

15 Apr 2015

Genetically modified Salmonella can help kill cancer cells

A new study has demonstrated that genetically modified Salmonella can be used to kill cancer cells. The study is published in this week's issue of mBio, an American Society for Microbiology online-only, open access journal.

15 Apr 2015

New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

Genzyme, a Sanofi company, announced today that new longer-term data on its relapsing multiple sclerosis treatments, Aubagio (teriflunomide) and Lemtrada (alemtuzumab), will be featured during the 67th annual meeting of the American Academy of Neurology being held in Washington, D.C. April 18-25.

15 Apr 2015

Johns Hopkins researchers named recipients of Hartwell’s 2014 Individual Biomedical Research Award

Gul Dolen, M.D., Ph.D., an assistant professor of neuroscience at the Johns Hopkins University School of Medicine, and Eili Y. Klein, Ph.D., an assistant professor of emergency medicine, are among 12 recipients of The Hartwell Foundation’s 2014 Individual Biomedical Research Award competition, the foundation announced on April 1.

15 Apr 2015

Researchers call for earlier PAH diagnosis and treatment

A study has found that treatment of pulmonary arterial hypertension in patients younger than 55 years significantly improves their performance on the 6-minute walk test.

14 Apr 2015

Early decline in 6MWT distance predicts PAH worsening

Research shows that an early decline in 6-minute walk test distance can predict worsening of disease in patients with pulmonary arterial hypertension.

14 Apr 2015

Phase–amplitude coupling changes may underlie DBS success in parkinsonism

Deep-brain stimulation of the subthalamic nucleus may improve motor symptoms in patients with Parkinson’s disease by reducing excessive cortical phase–amplitude coupling, researchers report in Nature Neuroscience.

14 Apr 2015

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Pharmalink AB, a specialty pharma company, today announces that the NEFIGAN Trial of Nefecon for the treatment of primary IgA nephropathy has fully met its primary efficacy endpoint at a planned interim analysis and been stopped early with respect to statistical analysis of the endpoint.

14 Apr 2015

LaVision BioTec reports on the Beatson Institute for Cancer Research and their use of multiphoton microscopy to understand the behaviour of cells in cancer metastasis

LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on the research of Professor Kurt I Anderson and his groups' studies of cell migration in the context of cancer metastasis at the Beatson Institute for Cancer Research...

14 Apr 2015

No effect of baseline cirrhosis on long-term TDF treatment outcomes

Research suggests that virological, serological and histological outcomes are comparable between cirrhotic and noncirrhotic patients with chronic hepatitis B virus infection undergoing long-term tenofovir disoproxil fumarate treatment.

13 Apr 2015

Therapy News and Research

Patterns of DNA anomalies can predict outcomes in women with ovarian cancer

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

UW researchers use Activa PC+S DBS system to treat essential tremor

Heroin-assisted treatments benefit some drug users

NIH-supported clinical trial to test statin use in patients with HIV-related cardiovascular disease

UH Seidman Cancer Center uses SpaceOAR System to perform first-ever prostate cancer treatment

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

Warfarin and PT-INR testing: an interview with Paul Wright, CEO, Universal Biosensors

Innovative liver cancer treatment gets EU approval

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

Genetically modified Salmonella can help kill cancer cells

New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

Johns Hopkins researchers named recipients of Hartwell’s 2014 Individual Biomedical Research Award

Researchers call for earlier PAH diagnosis and treatment

Early decline in 6MWT distance predicts PAH worsening

Phase–amplitude coupling changes may underlie DBS success in parkinsonism

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

LaVision BioTec reports on the Beatson Institute for Cancer Research and their use of multiphoton microscopy to understand the behaviour of cells in cancer metastasis

No effect of baseline cirrhosis on long-term TDF treatment outcomes

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News